Liver Neoplasms
Conditions
Brief summary
The purpose of this study is to evaluate the effectiveness and safety of a new biopsy track ablation device for liver biopsy.
Detailed description
Background: * Percutaneous biopsy for hepatic masses has a potential risk of bleeding and peritoneal tumor seeding. * A new device for biopsy track ablation has been invented to reduce the risk of bleeding and peritoneal tumor seeding. Method: * Routine percutaneous biopsy for hepatic masses is performed. * Immediate after obtaining tissue, biopsy needle track is ablated with a new biopsy tract ablator. * Immediate (with ultrasound) and 24 hours (with CT scan) after procedure, occurrence of complications is evaluated.
Interventions
DEVICEBiopsy Track Ablator (STARmed, Goyang, Korea)
After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
Sponsors
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients with a hepatic mass on CT scan or MRI * patients who are referred for percutaneous biopsy of a hepatic mass * patients with normal range of platelet count and coagulation test
Exclusion criteria
* pregnant women * patients with ascites * Uncooperative patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with complications | within 24 hours after procedure | If procedure-related complications are suspected clinically, appropriate tests such as CT scan or Ultrasound are performed and complications are evaluated. If procedure-related complications are not suspected, non-contrast CT scan is performed at 24 hours after procedure and complications are evaluated. |
Contacts
Primary ContactHyunchul Rhim, professor
Backup ContactKyoung Doo Song, professor
Outcome results
None listed